- Differentiate your antibody’s mechanism of action
- Strengthen your antibody’s intellectual property
- Success rate of >95% and 4–8 week turnaround time for select MAbs*
*SARS-CoV-2, Zika and, dengue MAbs
Questions? Call: 215-966-6061
Enabling the discovery of vaccines and antiviral therapeutics against SARS-CoV-2, dengue, Zika, and other viruses
Our industry-leading platforms help accelerate the development of your vaccines and therapeutics
We are in this together
SARS-CoV-2 Reporter Virus Particles (RVPs) are replication-incompetent pseudovirus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation
20 years of experience in virology and manufacturing pseudotyped Reporter Virus Particles
50+ virology publications on SARS-CoV-2, Ebola, Chikungunya, dengue, and more
“SARS-CoV-2 RVPs really helped us a lot since we did not have much previous expertise in SARS. The user meetings were especially helpful.”
*SARS-CoV-2, Zika and, dengue MAbs
“MPA technology quickly provided us with the reassurance that Abound Bio’s potent, neutralizing antibodies to SARS-CoV-2 did not bind off-target human membrane proteins which could be associated with toxicity.”
-John W. Mellors, MD, CEO, Abound Bio
Published in Li et al., 2020, Cell
See how Merck categorized RSV F glycoprotein antibodies from existing therapeutics
Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery and antibody discovery against viral targets.
RVPs incorporate virus-specific envelope proteins that are antigenically equivalent to those of live wild-type viruses. They contain a modified genome so they are safe and replication-incompetent.
RVPs are useful for high-throughput infectivity and neutralization assays. They are an efficient alternative to plaque assays.
Luciferase and GFP is used for quantitative read out.
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Join Our Mailing List